SCHEMBL18170087

SCHEMBL18170087

CCN(CC)CCc1cnn(COP(=O)(O)O)c1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20191322 0.82 S1PR1 (0.34) GAA
SCHEMBL20415636 0.75 S1PR1 (0.32)
SCHEMBL18176879 0.72 ALPI (0.39) GAA
SCHEMBL18169860 0.72
SCHEMBL18170086 0.70
SCHEMBL18169984 0.69
SCHEMBL18170040 0.69 MAPT (0.38)
SCHEMBL21409643 0.62 LPAR3 (0.48)
SCHEMBL29357505 0.60 FDPS (0.53)
SCHEMBL16181422 0.60 MTOR (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370808-B2 Pyrazole compounds and methods for making and using the compounds RIGEL PHARMACEUTICALS, INC. (US) 2022-06-28 US disclosed
EP-3286181-B1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS INC (US) 2021-01-27 EP disclosed
US-20190153006-A1 PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2019-05-23 US disclosed
US-10208074-B2 Pyrazole compounds and method for making and using the compounds RIGEL PHARMACEUTICALS, INC. (US) 2019-02-19 US disclosed
US-10208075-B2 Pyrazole compounds and method for making and using the compounds RIGEL PHARMACEUTICALS, INC. (US) 2019-02-19 US disclosed
US-20180208613-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2018-07-26 US disclosed
US-20180208612-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2018-07-26 US disclosed
US-9982000-B2 Pyrazole compounds and method for making and using the compounds RIGEL PHARMACEUTICALS, INC. (US) 2018-05-29 US disclosed
EP-3286181-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS Rigel Pharmaceuticals, Inc. (US) 2018-02-28 EP disclosed
WO-2016172560-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed
US-20160311839-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370808-B2 Pyrazole compounds and methods for making and using the compounds IRAK3, IRAK1, IRAK2 GAA 2438/4885
US-10208074-B2 Pyrazole compounds and method for making and using the compounds IRAK3, IRAK1, IRAK2 GAA 2472/4885
US-20190153006-A1 PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 GAA 2438/4885
US-20180208613-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 GAA 2472/4885
US-10208075-B2 Pyrazole compounds and method for making and using the compounds IRAK3, IRAK1, IRAK2 GAA 2472/4885
US-20180208612-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 GAA 2472/4885
US-20160311839-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 GAA 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.